Almac expands US & UK commercial facilities
October 22, 2013
Investments of over $20m enhance Almac’s commercial facilities on both sides of the Atlantic
With the opening of a new commercial packaging facility in the US and enhanced processing capabilities at the company’s Headquarters in Craigavon, UK, investments in the past year has substantially transformed the commercial business unit of Almac.
In Feb 2013, with FDA approval, Almac opened their US commercial packaging facility providing quality driven, flexible packaging solutions for both solid oral dosage forms and biopharmaceutical products.
Meanwhile, expansion continued at Almac’s UK commercial manufacturing and packaging facilities, with the completion of a US client led capital project in support of a key global product launch. This expansion has added significant capacity for commercial fluid bed drying and high speed encapsulation.
Additionally, in response to growing demand from a number of Japanese partners for enhanced flexibility related to larger blister sizes and requirement for non permeability and environmental protection, investment has also been made in state of the art blistering technology with product humidity control.
Due to record sales, growth in one of Almac’s client’s key products and entry into new markets including China, the most recent commercial expansion completed at the UK site was a client led second investment in dedicated facilities, doubling sachet output to 250 million sachets per annum.
David Downey, VP, Commercial Operations notes: “Almac continues to grow in partnership with our clients and is developing a strong reputation for the delivery of complex, time sensitive capital projects in support of growing, innovative products. This level of commercial investment demonstrates our commitment to building long term, strategic relationships.”
For further information on our commercial services, please visit us at CPhI booth # 42L08.
Notes to Editors
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,300 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with US operations based in Pennsylvania, North Carolina and California.